Navigation Links
A New Way to Treat Colon Cancer?

Researchers at University of Utah’s Huntsman Cancer Institute have discovered a new target for possible future colon cancer treatments – a molecule that is implicated in 85 percent of colon cancer cases. //

By knocking out – that is, genetically disabling – a molecule called C-Terminal Binding Protein (CTBP) researchers were able to rescue zebrafish from the effects of a mutation in the adenomatous polyposis coli (APC) gene.

In humans, mutations in this gene long have been known to initiate a series of events that cause colon polyps, which eventually become cancerous. APC mutations play a role in 85 percent of colon cancers. The new findings mean CTBP also is involved in that proportion of colon cancers.

In zebrafish, APC mutations keep the intestine from developing properly. “In essence, knocking out CTPB promotes normal development of the intestine in zebrafish carrying an APC mutation,” says David A. Jones, a University of Utah associate professor of oncological sciences and leader of the study.

In normal cells of both humans and zebrafish, the APC gene controls the amount of CTBP present by marking it for destruction. In tumor cells with mutated APC, CTPB is not destroyed; instead it accumulates in the cell.

One function of CTBP is to turn off the process that converts vitamin A into retinoic acid in the cell. Retinoic acid is essential in cell differentiation – the function that determines what type of cell forms and how long it lives. This study observed that in both zebrafish and human tissues with APC mutations, there are high CTBP levels and low capability to produce retinoic acid. In APC-mutated tissues in which CTBP had been “knocked out,” retinoic acid production was restored.

Earlier studies in Jones’ lab showed that lack of retinoic acid caused zebrafish intestines to form incorrectly, and that adding retinoic acid corrected the problems.

"Knocking out CTBP does exactly the same thing, and the logical conclusion is that it’s because CTBP controls retinoic acid production,” says Jones. “Since CTBP is a completely new target, we must now look for potential chemical agents that would work to block its actions. That could take three to five years.”

Source-Neswise
SRM
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. New FDA Approved Drug To Treat Migraine
4. Treatment for Menieres disease
5. Treatment for pre-menstrual syndrome is ineffective
6. Angiotensin-II-receptor blockers - Treat kidney failure
7. Cipro Has Cheaper Cousins to Treat Anthrax
8. Better Treatment for obesity
9. Gene Treatment for Heart Disease
10. Cyclosporin A Treats Leukemia Complications
11. New Way To Treat Lupus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... The ... its fully redesigned website, which launched October 17, 2016, features comprehensive information regarding ... and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Delete® - Tattoo ... Time For The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® ... is providing the Phoenix Valley with Delightful Deals on Botox® and Juvederm® ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors to create ... Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip book ... Editors can select from a variety of flip book animations. In Addition, users can ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  The Corporate Whistleblower Center ... call them anytime at 866-714-6466 if they possess proof ... more drugs. Aside from the innocent patients frequently being the ... because often-times these practices target Medicare recipients or the elderly. ... ...
(Date:12/7/2016)... READING, Mass. , Dec. 7, 2016 /PRNewswire/ ... and Trace Network for connecting the Life Sciences ... the global marketplace, today announced that Tjoapack has ... European pharmaceutical manufacturing customers comply with the rapidly ... Chain Security Act (DSCSA) in 2017 and the ...
(Date:12/7/2016)... 7, 2016 According to responses from U.S. oncologists ... (38%) of patients with non-small cell lung cancer (NSCLC), treatment ... (EGFR) genetic mutation status. The findings of the survey were ... #6067 #P3.02b ) at the 2016 World Conference on ... The survey results revealed an overall high rate ...
Breaking Medicine Technology: